Various ‘push-and-pull’ mechanisms have been tried to attract pharmaceutical companies into medical innovation for public ...
PTC Therapeutics may reeling from the failure of its amyotrophic lateral sclerosis (ALS) drug utreloxastat yesterday, but the ...
Merus partners with Partner Therapeutics for U.S. rights to Zeno in NRG1+ cancer. Updated petosemtamab data emerge as a key ...
Space on MSN12d
Mass Effect: The Board Game — Priority: Hagalaz reviewIt's been 17 long years since we last cruised around the galaxy aboard the SSV Normandy, but we're finally back thanks to ...
(RTTNews) - PTC Therapeutics (PTCT) has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher for $150 million upon the closing of the transaction. The company was ...
WARREN, N.J., Nov. 27, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback